Innate Pharma (IPHA) Non-Current Deffered Revenue (2017 - 2024)

Innate Pharma (IPHA) has disclosed Non-Current Deffered Revenue for 8 consecutive years, with $3.0 million as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Non-Current Deffered Revenue fell 39.24% year-over-year to $3.0 million, compared with a TTM value of $3.0 million through Dec 2024, down 39.24%, and an annual FY2024 reading of $3.1 million, down 38.79% over the prior year.
  • Non-Current Deffered Revenue was $3.0 million for Q4 2024 at Innate Pharma, down from $5.0 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $39.0 million in Q4 2020 and bottomed at $3.0 million in Q4 2024.
  • Average Non-Current Deffered Revenue over 5 years is $16.8 million, with a median of $8.1 million recorded in 2022.
  • The sharpest move saw Non-Current Deffered Revenue dropped 12.76% in 2020, then tumbled 72.2% in 2022.
  • Year by year, Non-Current Deffered Revenue stood at $39.0 million in 2020, then fell by 25.37% to $29.1 million in 2021, then crashed by 72.2% to $8.1 million in 2022, then crashed by 38.52% to $5.0 million in 2023, then tumbled by 39.24% to $3.0 million in 2024.
  • Business Quant data shows Non-Current Deffered Revenue for IPHA at $3.0 million in Q4 2024, $5.0 million in Q4 2023, and $8.1 million in Q4 2022.